Erbitux cetuximab: Phase II data

The open-label, international Phase II BALI-1 trial in 173 patients showed that Erbitux plus cisplatin missed the primary endpoint of significantly improving ORR vs. cisplatin alone (20% vs. 10.3%, p=...